Amal A Wanigatunga1,2, Ravi Varadhan2,3, Eleanor M Simonsick4, Olga D Carlson4, Stephanie Studenski4, Luigi Ferrucci4, Jennifer A Schrack1,2,4. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. Center on Aging and Health, Johns Hopkins University and Medical Institutions, Baltimore, Maryland. 3. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Intramural Research Program, National Institute on Aging, Baltimore, Maryland.
Abstract
BACKGROUND: Chronically elevated interleukin-6 (IL-6) levels contribute to fatigue and functional decline via multiple pathways that often lead to frailty. Lesser known is the contribution of IL-6 to fatigue in relation to a standardized workload (fatigability), a precursor to functional decline. Therefore, the purpose of this study was to examine the longitudinal relationship between IL-6 and fatigability. METHODS: About 985 participants from the Baltimore Longitudinal Study of Aging (mean age: 70 ± 10 years) were evaluated every 1-4 years. IL-6 was measured in fasting serum samples at each visit and log-transformed for analyses. Perceived fatigability (PF) was defined as self-reported exertion (rate of perceived exertion; RPE) after a 5-min, 0.67 m/s, 0% grade treadmill walk. Continuous and categorical associations between IL-6 (baseline and repeated measures) and PF were assessed using generalized estimating equations, adjusting for demographics, behavioral factors, and comorbid conditions. RESULTS: In fully adjusted continuous models, twofold higher baseline IL-6 was associated with a 0.28 higher RPE (p = .03). This relationship tended to remain constant annually (baseline log IL-6 by time interaction p = .29). To provide clinical relevance, the sample median (3.7 pg/mL) was used to examine high versus low IL-6 levels. Over time, the high group reported an average 0.25 higher RPE (p = .03) than the low group. Annual change in logged IL-6 was not associated with annual change in PF (p = .48). CONCLUSION: Findings suggest that elevated IL-6 is a biomarker of physiological dysregulation associated with greater fatigability, but there is no longitudinal association between IL-6 and fatigability. Future studies should evaluate whether interventions that aim to reduce inflammation also attenuate fatigability.
BACKGROUND: Chronically elevated interleukin-6 (IL-6) levels contribute to fatigue and functional decline via multiple pathways that often lead to frailty. Lesser known is the contribution of IL-6 to fatigue in relation to a standardized workload (fatigability), a precursor to functional decline. Therefore, the purpose of this study was to examine the longitudinal relationship between IL-6 and fatigability. METHODS: About 985 participants from the Baltimore Longitudinal Study of Aging (mean age: 70 ± 10 years) were evaluated every 1-4 years. IL-6 was measured in fasting serum samples at each visit and log-transformed for analyses. Perceived fatigability (PF) was defined as self-reported exertion (rate of perceived exertion; RPE) after a 5-min, 0.67 m/s, 0% grade treadmill walk. Continuous and categorical associations between IL-6 (baseline and repeated measures) and PF were assessed using generalized estimating equations, adjusting for demographics, behavioral factors, and comorbid conditions. RESULTS: In fully adjusted continuous models, twofold higher baseline IL-6 was associated with a 0.28 higher RPE (p = .03). This relationship tended to remain constant annually (baseline log IL-6 by time interaction p = .29). To provide clinical relevance, the sample median (3.7 pg/mL) was used to examine high versus low IL-6 levels. Over time, the high group reported an average 0.25 higher RPE (p = .03) than the low group. Annual change in logged IL-6 was not associated with annual change in PF (p = .48). CONCLUSION: Findings suggest that elevated IL-6 is a biomarker of physiological dysregulation associated with greater fatigability, but there is no longitudinal association between IL-6 and fatigability. Future studies should evaluate whether interventions that aim to reduce inflammation also attenuate fatigability.
Authors: Luigi Ferrucci; Brenda W J H Penninx; Stefano Volpato; Tamara B Harris; Karen Bandeen-Roche; Jennifer Balfour; Suzanne G Leveille; Linda P Fried; Jack M Guralnik Md Journal: J Am Geriatr Soc Date: 2002-12 Impact factor: 5.562
Authors: Martica H Hall; Stephen F Smagula; Robert M Boudreau; Hilsa N Ayonayon; Suzanne E Goldman; Tamara B Harris; Barbara L Naydeck; Susan M Rubin; Laura Samuelsson; Suzanne Satterfield; Katie L Stone; Marjolein Visser; Anne B Newman Journal: Sleep Date: 2015-02-01 Impact factor: 5.849
Authors: Rudy J Valentine; Jeffrey A Woods; Edward McAuley; Robert Dantzer; Ellen M Evans Journal: Brain Behav Immun Date: 2011-06-13 Impact factor: 7.217
Authors: Eleanor M Simonsick; Nancy W Glynn; Gerald J Jerome; Michelle Shardell; Jennifer A Schrack; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2016-06-02 Impact factor: 5.562
Authors: Matteo Cesari; Brenda W J H Penninx; Marco Pahor; Fulvio Lauretani; Anna Maria Corsi; G Rhys Williams; Jack M Guralnik; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Jennifer A Schrack; Amal A Wanigatunga; Vadim Zipunnikov; Pei-Lun Kuo; Eleanor M Simonsick; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-16 Impact factor: 6.053
Authors: Yujia Susanna Qiao; Jaroslaw Harezlak; Kyle D Moored; Jacek K Urbanek; Robert M Boudreau; Pamela E Toto; Marquis Hawkins; Adam J Santanasto; Jennifer A Schrack; Eleanor M Simonsick; Nancy W Glynn Journal: Med Sci Sports Exerc Date: 2022-06-24
Authors: Thomas Chan; Amal A Wanigatunga; Antonio Terracciano; Michelle C Carlson; Karen Bandeen-Roche; Paul T Costa; Eleanor M Simonsick; Jennifer A Schrack Journal: Psychol Aging Date: 2021-09
Authors: Roland von Känel; Paul J Mills; Joel E Dimsdale; Michael G Ziegler; Matthew A Allison; Thomas L Patterson; Sonia Ancoli-Israel; Christopher Pruitt; Igor Grant; Brent T Mausbach Journal: J Gerontol A Biol Sci Med Sci Date: 2020-10-15 Impact factor: 6.053
Authors: Cutter A Lindbergh; Kaitlin B Casaletto; Adam M Staffaroni; Fanny Elahi; Samantha M Walters; Michelle You; John Neuhaus; Will Rivera Contreras; Paul Wang; Anna Karydas; Jesse Brown; Amy Wolf; Howie Rosen; Yann Cobigo; Joel H Kramer Journal: J Gerontol A Biol Sci Med Sci Date: 2020-07-13 Impact factor: 6.053
Authors: Elizabeth A Salerno; Amal A Wanigatunga; Yang An; Jacek K Urbanek; Eleanor M Simonsick; Luigi Ferrucci; Susan M Resnick; Jennifer A Schrack Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-16 Impact factor: 6.053
Authors: Alfonso J Alfini; Jennifer A Schrack; Jacek K Urbanek; Amal A Wanigatunga; Sarah K Wanigatunga; Vadim Zipunnikov; Luigi Ferrucci; Eleanor M Simonsick; Adam P Spira Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-16 Impact factor: 6.591
Authors: Pablo Martinez-Amezcua; Eleanor M Simonsick; Amal A Wanigatunga; Jacek K Urbanek; Nancy Chiles Shaffer; Luigi Ferrucci; Jennifer A Schrack Journal: Obesity (Silver Spring) Date: 2019-05-25 Impact factor: 5.002
Authors: Yujia Qiao; Pablo Martinez-Amezcua; Amal A Wanigatunga; Jacek K Urbanek; Eleanor M Simonsick; Luigi Ferrucci; Jennifer A Schrack Journal: J Am Heart Assoc Date: 2019-08-14 Impact factor: 5.501